Precigen, Inc. - Common Stock (PGEN)
3.8900
+0.7900 (25.48%)
NASDAQ · Last Trade: Mar 26th, 6:39 PM EDT
Detailed Quote
| Previous Close | 3.100 |
|---|---|
| Open | 4.070 |
| Bid | 3.880 |
| Ask | 3.890 |
| Day's Range | 3.730 - 4.275 |
| 52 Week Range | 1.110 - 5.465 |
| Volume | 23,491,444 |
| Market Cap | 981.91M |
| PE Ratio (TTM) | -2.799 |
| EPS (TTM) | -1.4 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,169,699 |
Chart
About Precigen, Inc. - Common Stock (PGEN)
Precigen Inc is a biotechnology company focused on developing innovative gene and cell therapies aimed at addressing a range of diseases, including cancer and genetic disorders. The company leverages its proprietary technologies to create advanced therapeutic solutions that aim to enhance the body's immune response and provide targeted treatment options. By utilizing its expertise in genetic engineering and immunology, Precigen works to bring transformative health solutions to patients while advancing the field of precision medicine. Read More
News & Press Releases
Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating estimates but sales of $4.565 million falling short.
Via Benzinga · March 26, 2026
Thursday's session: gap up and gap down stockschartmill.com
Via Chartmill · March 26, 2026
These stocks that are showing activity before the opening bell on Thursday.chartmill.com
Via Chartmill · March 26, 2026

Precigen (PGEN) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 25, 2026
Precigen Inc (NASDAQ:PGEN) Stock Surges on Narrower Loss and Commercial Transition After FDA Approvalchartmill.com
Via Chartmill · March 25, 2026
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?fool.com
Via The Motley Fool · December 2, 2025
Stay updated with the stocks that are on the move in today's after-hours session.chartmill.com
Via Chartmill · March 25, 2026
This vacation ownership firm serves over 700,000 members and generates recurring revenue from real estate, financing, and resort operations.
Via The Motley Fool · January 24, 2026
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via Chartmill · November 14, 2025
Via Benzinga · November 14, 2025
Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS.
Via Chartmill · November 13, 2025
Precigen (PGEN) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 13, 2025
Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares
Via The Motley Fool · November 1, 2025
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.
Via The Motley Fool · September 7, 2025
Via Benzinga · September 3, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · August 22, 2025
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via Chartmill · August 21, 2025
Via Benzinga · August 21, 2025
Via Benzinga · August 19, 2025
Via Benzinga · August 19, 2025
Via Benzinga · August 19, 2025
Loop Industries, Inc. (Nasdaq: LOOP) just inked a game-changing alliance with Shinkong Synthetic Fibers, part of Taiwan’s $ multi-billion Shin Kong Group , to accelerate worldwide adoption of Twist™ , Loop’s branded 100% recycled textile-to-textile polyester resin.
Via AB Newswire · August 15, 2025
Via Benzinga · August 15, 2025
